Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Development of Multifunctional Targeted Dual-Loaded Polymeric Nanoparticles for Triple-Negative Breast Cancer Treatment

Pharmaceutics(2025)10.3390/pharmaceutics17040425Source: DataRank Database

Development of Multifunctional Targeted Dual-Loaded Polymeric Nanoparticles for Triple-Negative Breast Cancer Treatment is a research paper published in Pharmaceutics (2025). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 1.01)OA: goldTopics (36)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Emmanuel O. Akala ORCID,Gantumur Battogtokh ORCID

Live enrichment

PubMed:40284424 PMC:PMC12030066 OpenAlex:https://openalex.org/W4408919780

NIH/NIGMS

Grant: #1 R16GM145483-01

NIH/NIGMS

Grant: #1 C06 RR 020608-01

NIH/NIGMS

Grant: #1 C06 RR 14469-01

NIGMS NIH HHS

Grant: R16 GM145483

NIH HHS

Grant: NIH/NIGMS Grant #1 R16GM145483-01

National Institutes of Health

Grant: 1C06RR020608-01

EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM: REN*: PHARMACOLOGY

National Institutes of Health

Grant: 1R16GM145483-01

Multifunctional Nanotechnology Platform for Triple Negative Breast Cancer Treatment

FWCI

1.01

Citation Percentile

0.7%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/1999-4923/17/4/425/pdf?version=1743074204

publisherhttps://www.mdpi.com/1999-4923/17/4/425/pdf?version=1743074204

publisherhttps://www.mdpi.com/1999-4923/17/4/425/pdf

journalhttps://doi.org/10.3390/pharmaceutics17040425

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40284424

Fields of Study

Nanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsCancer Treatment and Pharmacology02 engineering and technology0210 nano-technology

Keywords

Triple-negative breast cancerPaclitaxelBreast cancerIn vivoCetuximabCisplatinCytotoxicityCancer researchTargeted therapyChemistryPharmacologyDrug deliveryChemotherapyMedicineCancerMaterials scienceIn vitroMonoclonal antibodyNanotechnologyInternal medicineImmunologyAntibodyBiologyBiochemistryCopolymerTnbcDual-drug LoadingCetuximab Nanoparticle ConjugateRS1-441Pharmacy and materia medicaArticle

Sustainable Development Goals

SDG 0: Good health and well-being